UPB
NASDAQ · Biotechnology
Upstream Bio Inc
$9.47
+1.02 (+12.07%)
Open$8.68
Previous Close$8.45
Day High$9.57
Day Low$8.67
52W High$33.68
52W Low$5.14
Volume—
Avg Volume919.4K
Market Cap452.84M
P/E Ratio—
EPS$-2.29
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+160.6% upside
Current
$9.47
$9.47
Target
$24.68
$24.68
$18.50
$24.68 avg
$35.72
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.50M | 198.99M | 177.59M |
| Net Income | -66,105,406 | -4,151,490 | -3,219,143 |
| Profit Margin | -2,650.0% | -2.1% | -1.8% |
| EBITDA | -78,772,051 | -5,330,036 | -5,179,349 |
| Free Cash Flow | — | -2,620,505 | -3,332,995 |
| Rev Growth | — | +14.1% | -5.8% |
| Debt/Equity | — | 0.66 | 0.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |